Life Sciences



Transaction type Public M&A

Sector Life Sciences

finnCap have advised Ligand UK, a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated (Ligand), on their acquisition of Vernalis PLC.

Ligand is a NASDAQ listed biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.

Commenting on the Acquisition, Dr. Peter Fellner, Chairman of Vernalis, said:

“On behalf of the Board, following the formal sale process that the business initiated in March this year, I am pleased to recommend the acquisition of Vernalis by the Ligand Group to all Vernalis Shareholders. The Board was pleased with the interest the Company received as part of the formal sale process and believes the cash offer from the Ligand Group represents the best value for all Vernalis shareholders.”